Glucose Control With Multiple Daily Insulin Injections In Diabetic Patients Hospitalized In A General Medicine Ward

Sponsor
Assaf-Harofeh Medical Center (Other)
Overall Status
Terminated
CT.gov ID
NCT00464854
Collaborator
(none)
100
1
14
7.1

Study Details

Study Description

Brief Summary

At least 20% of patients hospitalized in the general medical and surgical wards at any given time suffer from diabetes. It has been demonstrated that poor clinical outcome correlates with the degree of hyperglycemia in these patients. Strict glucose control in hospitalized patients improves clinical outcomes in the setting of acute myocardial infarction, cardiac surgical procedures, infection and critical illness in patients hospitalized in intensive care units if insulin is applied intravenously. It is, however, complex to obtain strict glucose control in the general surgical and medical wards. These wards are usually understaffed as compared to intensive care units and therefore are incapable to perform the necessary close monitoring essential in patients treated with intravenous insulin. We intend to test the feasibility of glucose control by multiple daily subcutaneous injections with long acting basal glargine insulin and pre-meal insulin analogues. If good glucose control can be achieved, this would be a valid, more convenient and acceptable alternative to intravenous insulin infusions to obtain good glucose control in diabetic patients hospitalized in general internal medicine wards.

Condition or Disease Intervention/Treatment Phase
  • Drug: Glargine and insulin aspart or lispro
N/A

Detailed Description

Location of the study:
Internal Medicine Wards C of Assaf Harofe Medical Center, Zerifin, Israel:
Inclusion Criteria:
  • Adult (<18 years) Male and female T1 & T2DM patients who can sign an informed consent.

  • Insulin treatment (at least one injection a day) prior to hospitalization for at least half a year.

Exclusion Criteria:
  • Diabetic ketoacidosis.

  • Hyperosmolar state due to hyperglycemia.

  • Pregnancy

  • Fertile women who do not use oral contraception or IUD

Concurrent medications:

ยท The hospital staff will determine the initiation or continuation of oral and intravenous medications as indicated by the patient's medical status.

Admission Blood tests:
  • Routine: CBC, Creatinine, Urea, Na, K, GOT, GPT, Alp, Albumin, Glu

  • HbA1C & Fructosamine.

Initiation and Titration of Insulin dosage:
  • Glargine insulin will be initiated as a function of the first fasting glucose level and the patients body weight (0.3 - 0.8 U/kg). Up- or down titration will occur every morning by 10 - 20% according to capillary am fasting glucose (goal 130 mg%). The dosage of premeal insulin analogues will be based according to a sliding scale and calculated as a percentage of the amount of am glargine.

  • Capillary blood glucose levels were measured seven times a day: before and two hours after breakfast, lunch and dinner and at bedtime. Additional measurements were performed according to clinical needs such as suspected hypoglycemia or unexplained deterioration of clinical condition

Study Design

Study Type:
Interventional
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Feasiblity, Safety And Efficacy Of Glucose Control With Multiple Daily Insulin Injections In Diabetic Patients Hospitalized In A General Medicine Ward
Study Start Date :
Jul 1, 2005
Actual Study Completion Date :
Sep 1, 2006

Outcome Measures

Primary Outcome Measures

  1. Achievement of a fasting blood glucose of 130 mg/dl and a mean daily glucose level of 180 mg/dl during hospitalization []

Secondary Outcome Measures

  1. Hypoglycemia of < 60 mg% (symptomatic and asymptomatic) []

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult (<18 years) Male and female T1 & T2DM patients who can sign an informed consent.

  • Insulin treatment (at least one injection a day) prior to hospitalization for at least half a year.

Exclusion Criteria:
  • Diabetic ketoacidosis.

  • Hyperosmolar state due to hyperglycemia.

  • Pregnancy

  • Fertile women who do not use oral contraception or IUD

Contacts and Locations

Locations

Site City State Country Postal Code
1 Assaf Harofe Medical Center Zerifin Israel 70300

Sponsors and Collaborators

  • Assaf-Harofeh Medical Center

Investigators

  • Principal Investigator: Andreas E Buchs, M.D., Assaf Harofe Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00464854
Other Study ID Numbers:
  • AH-2323
First Posted:
Apr 24, 2007
Last Update Posted:
Apr 24, 2007
Last Verified:
Apr 1, 2007
Keywords provided by , ,
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 24, 2007